Abstract Library

#4520 Is late diagnosis and carcinoid heart disease (CaHD) associated with deprivation index? – An audit of practice and assessment of deprivation index in Sheffield ENETS Centre of Excellence

Introduction: Delays to diagnosis in neuroendocrine neoplasms is a world-wide problem. Challenges and inequities recognised include low awareness and access to expert centres. Indices of multiple deprivation (IMD) assess the least to the most deprived areas in the UK, 1 being the most deprived of the 10 deciles.

Conference:

Presenting Author: Munir A

Authors: Abdella O, Abdelhaleem E, Kwok W, Harber J, Rowett O,

Keywords: Index of multiple deprivation, carcinoid syndrome, carcinoid heart disease,

#4094 Peptide Receptor Radionuclide Therapy improves progression free and overall survival in patients who progress after resection of gastroenteropancreatic NETs

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) improves progression-free-survival (PFS) in advanced midgut neuroendocrine tumors (NETs). Whether PRRT specifically improves survival in surgically managed gastroenteropancreatic (GEP) NET with progression is unknown.

Conference:

Presenting Author: Howe J

Authors: Borbon L, Sherman S, Breheny P, Ear P, Menda Y,

Keywords: gastroenteropancreatic, resection, progression, PRRT, neuroendocrine tumor,

#3759 Long-term outcomes of surgical valve replacement in patients with severe carcinoid heart disease

Introduction: Carcinoid Heart Disease (CHD) is a complex complication of carcinoid syndrome (CS), with Surgical Valve Replacement (SVR) being its established treatment in selected patients.

Conference:

Presenting Author: Hayes A

Authors: Matti J, Crompton J, Furtado O'Mahony L, Hayes A, Harrison T,

Keywords: Carcinoid Heart Disease, Valve Replacement, Carcinoid Syndrome, Overall Survival,

#3465 Opposite treatment approach in two institutes identifies primary tumor resection to be associated with improved disease specific mortality in patients with stage IV small intestinal neuroendocrine tumors (SI-NET) vs watch-and-wait strategy

Introduction: SI-NET often present with metastatic disease. There is an ongoing debate whether or not to perform primary tumor resection (PTR) in stage IV SI-NET.

Conference:

Presenting Author: Levy S

Authors: Levy S, Arthur J, Banks M, Kok N, Fenwick S,

Keywords: SI-NET, surgical approach, stage 4, instrumental variable,

#3327 Increased expression of cytochrome P450 3A4 in pancreatic neuroendocrine tumor cells promotes drug resistance

Introduction: Pancreatic neuroendocrine tumors (PNETs) are slow growing, but often metastasize to the liver. Several systemic treatment options are available for metastatic PNETs but unfortunately fail to improve survival. Hence a better understanding of PNET biology and new therapies are required. In an attempt to identify new drugs for metastatic PNETs, our group performed gene expression analysis of primary PNETs and PNETs that metastasized to lymph nodes and/or liver and identified genes and drug candidates that could potentially help treat metastatic PNETs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Tran C

Authors: Tran C, Li G, Sherman S, Howe J, Ear P,

Keywords: PNET, metastases, drug resistance, liver microenvironment, etoposide, CYP3A4,